Intradialytic hypertension affects 10-15% of hemodialysis patients and is associated with increased mortality, prompting recent studies into various pharmacological and nonpharmacological treatments.
This review summarizes current evidence on the pathophysiology and management of intradialytic hypertension, highlighting the need for further research.
Intradialytic hypertension (IDH), that is, a paradoxical rise in blood pressure (BP) during or immediately after a hemodialysis session, affects approximately 10-15% of the hemodialysis population. It is currently recognized as a phenomenon of major clinical significance as recent studies have shown that BP elevation extends to the whole interdialytic interval and associates with increased cardiovascular and all-cause mortality. The pathophysiology of IDH is complex involving volume and sodium overload, endothelial dysfunction, excess renin-angiotensin-aldosterone system and sympathetic nervous system activation, and other mechanisms. For several years, there was a scarcity of studies regarding IDH treatment; recently, however, several attempts to examine the effect of nonpharmacological and pharmacological measures on BP levels in IDH are made. This review attempts to summarize this latest evidence in the field of management of IDH and discuss areas for future research.
Iatridi et al. (Mon,) conducted a review in Intradialytic hypertension. Nonpharmacological and pharmacological measures was evaluated. Intradialytic hypertension affects 10-15% of hemodialysis patients and is associated with increased mortality, prompting recent studies into various pharmacological and nonpharmacological treatments.